APA
Aggarwal, Mohit & Villuendas, Raquel & Gomez, Gonzalo & Rodriguez Pinilla, Socorro M & Sánchez Beato, Margarita & Alvarez, David & Martinez, Nerea & Rodriguez, Antonia & Castillo, María Encarnación & Camacho, Francisca I & Montes Moreno, Santiago & Garcia Marco, Jose A & Kimby, Eva & Pisano, David G & Piris, Miguel A (2008-09 ) .TCL1A expression delineates biological and clinical variability in B-cell lymphoma.
ISO 690
Aggarwal, Mohit & Villuendas, Raquel & Gomez, Gonzalo & Rodriguez Pinilla, Socorro M & Sánchez Beato, Margarita & Alvarez, David & Martinez, Nerea & Rodriguez, Antonia & Castillo, María Encarnación & Camacho, Francisca I & Montes Moreno, Santiago & Garcia Marco, Jose A & Kimby, Eva & Pisano, David G & Piris, Miguel A. 2008-09 .TCL1A expression delineates biological and clinical variability in B-cell lymphoma.
https://hdl.handle.net/20.500.12080/39548
Résumé:
The assembly of a collection of gene-expression signatures of the major types of B-cell non-Hodgkin¿s
lymphoma has identified increased T-cell leukemia/lymphoma 1A (TCL1) expression in multiple lymphoma
types and cases, and has enabled the investigation of the functional and clinical importance of TCL1
expression. Specifically, Burkitt¿s lymphoma cases show a homogeneously strong expression of TCL1,
whereas diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic
leukemia, nodal marginal zone lymphoma, and splenic marginal zone lymphoma display a striking variability in
the intensity of TCL1 staining. This was validated in two independent series. A Gene-Set Enrichment Analysis of
the genes correlated with TCL1A expression found that variation in the level of expression of TCL1A was
significantly associated with some of the most important gene signatures recognizing B-cell lymphoma
pathogenesis and heterogeneity, such as germinal center, B-cell receptor, NF-jB (and its target genes), death,
MAP kinases, TNFR1, TOLL, and IL1R. Additionally, TCL1 expression was correlated with shorter time to
treatment in chronic lymphocytic leukemia cases and shorter lymphoma-specific survival in mantle cell
lymphoma series, thus indicating the clinical and biological significance of TCL1 expression, and suggesting
TCL1A as a potential therapeutic target